| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4fd60bb8460eae787d3422214e996593
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_120c768e7747abf40e35ab36af4beaed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6f1c676d6affa4f84e50a707b23c4139
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_11bb081fd965ecd11e7dcb44b8797e25 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70571
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-05 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B59-002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0468 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-08 |
| filingDate |
2022-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d75fc8ab07d8672e737bb4a02a9a805
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c3a6a6dae1e8cba3b0ee7497e57bc2e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5814d8e7d299c38eed01e6a8a14ec41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2daba2e73006bceb69470a93077f00d9 |
| publicationDate |
2022-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022255915-A1 |
| titleOfInvention |
Pet radiotracers |
| abstract |
The compounds of the invention are ASEM analogs with different ortho- and para-substitutions that can be labelled with 3H and/or 11C to be used as PET radiotracers capable of binding to α7-nAChR both in vitro and in vivo in a subject body. The PET radiotracers thereby enable visualization and quantification of α7-nAChR in various target tissues, including monitoring the distribution of α7-nAChRs in such a target tissue. The compounds exhibit of high binding affinity and specificity towards α7-nAChR and are able to pass the blood-brain barrier (BBB). |
| priorityDate |
2021-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |